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Available online 25 March 2016Metformin is used as a probe for OCT2 mediated transport when investigating possible DDIs with new chemical
entities. The aim of the current study was to investigate the ability of physiologically-based pharmacokinetic
(PBPK) models to simulate the effects of OCT and MATE inhibition by cimetidine on metformin kinetics. PBPK
models were developed, incorporating mechanistic kidney and liver sub-models for metformin (OCT and
MATE substrate) and a mechanistic kidney sub-model for cimetidine. The models were used to simulate inhibi-
tion of theMATE1,MATE2-K, OCT1 andOCT2mediated transport ofmetformin by cimetidine. Assuming compet-
itive inhibition and using cimetidine Ki values determined in vitro, the predicted metformin AUC ratio was 1.0
compared to an observed value of 1.46. The observed AUC ratio could only be recovered with this model when
the cimetidine Ki for OCT2 was decreased 1000-fold or the Ki's for both OCT1 and OCT2 were decreased 500-
fold. An alternative description of metformin renal transport by OCT1 and OCT2, incorporating electrochemical
modulation of the rate of metformin uptake together with 8–18-fold decreases in cimetidine Ki's for OCTs and
MATEs, allowed recovery of the extent of the observed effect of cimetidine on metformin AUC. While the ﬁnal
PBPK model has limitations, it demonstrates the beneﬁt of allowing for the complexities of passive permeability
combined with active cellular uptake modulated by an electrochemical gradient and active efﬂux.
© 2016 Simcyp Limited. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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B.V. This is an open access article unphysiological pH, its pharmacokinetic behaviour is dictated largely by
the inﬂuence of transporters (Graham et al., 2011). The physicochemi-
cal properties of metformin also determine that its elimination is pre-
dominantly by renal excretion (80%), with a minor contribution from
metabolism (Sirtori et al., 1978; Tucker et al., 1981). While the magni-
tudes of documented drug–drug interactions (DDIs) affecting metfor-
min as a victim are not of major clinical signiﬁcance, the compound is
recommended by the US FDA as a probe for OCT2 mediated transport
when investigating possible DDIs with new chemical entities (U.S.
Department of Health and Human Services et al., 2012). On this basis,
a sound mechanistic understanding of DDIs with metformin is impor-
tant. Such DDIs, involving raised drug exposure in the kidney, are not
necessarily reﬂected in an equivalent change in systemic exposure
(Sprowl and Sparreboom, 2014).
Within the proximal tubule cells of the kidney, metformin is actively
transported across the basal membrane by OCT2 and efﬂuxed into the
tubular ﬂuid at the apical membrane by MATE1 and MATE2-K
(Koepsell et al., 2007; Pelis and Wright, 2011). In hepatocytes it has
been shown to be a substrate for OCT1 expressed on the sinusoidal
membrane (Koepsell, 2011). Although MATE1 is expressed on the can-
alicular membrane of hepatocytes, biliary clearance of metformin isder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pears to be signiﬁcant (Proctor et al., 2008), while metformin has also
been shown to be a substrate for OCT1, OCT3 and PMAT at the apical
membrane of enterocytes (Muller et al., 2005; Zhou et al., 2007).Metab-
olism ofmetformin by CYP3A4 has been reported based on studieswith
recombinant enzyme (Choi et al., 2010).
Co-administration of cimetidine, pyrimethamine, trimethoprim,
lansoprazole, dolutegravir and vandetanib with metformin has been
shown to increase its AUC by 1.2 to 1.7-fold (Ding et al., 2014; Grun
et al., 2013; Johansson et al., 2014; Kusuhara et al., 2011; Somogyi
et al., 1987;Wang et al., 2008; Zong et al., 2014). All of these compounds
are inhibitors of OCT2, while cimetidine, pyrimethamine and trimetho-
prim are also reported to be inhibitors ofMATE transporters. Cimetidine
Ki values for MATE1 and MATE2-K are, respectively, 62- and 40-fold
lower than those for OCT2 inhibition, suggesting that the latter is un-
likely to be signiﬁcant after therapeutic doses of cimetidine (Ito et al.,
2012; Tsuda et al., 2009). Similarly, pyrimethamine Ki values for
MATE1 and MATE2-K are 118- and 193-fold lower than those for
OCT2 inhibition, respectively (Ito et al., 2010; Kusuhara et al., 2011).
The incorporation of permeability-limited uptake models within
conventional PBPK models has been shown to improve insight into
transporter mediated DDIs in the liver (Li et al., 2014). However, exam-
pleswhere this approach has been used to simulate transportermediat-
ed DDIs in the kidney are rare. Posada et al. (2015) used a mechanistic
kidney model to simulate the increase in pemetrexed exposure due to
inhibition of renal OAT3 uptake by ibuprofen. Hsu et al. (2014) investi-
gated DDIs between probenecid and three renally cleared drugs using a
similar approach. However, in vitro data for the inhibition of speciﬁc
transporters by probenecid were not applied, obscuring understanding
of the impact of the relative inhibition of uptake and efﬂux transporters.
In addition, permeability-limited PBPKmodels typically assume that ac-
tive transport will follow ﬁrst-order orMichaelis–Menten kinetics, with
little acknowledgement of the mechanism(s) of transport. The driving
force for transport varies greatly amongst the known drug transporters.
For example, despite OCT and MATE both being solute carriers, trans-
port by the former is driven by the electrochemical gradient across the
cell membrane while the latter is an antiporter of protons (Pelis and
Wright, 2011).
We describe an attempt to simulate reported effects of cimetidine on
the kinetics of metformin using a PBPK model incorporating active up-
take and efﬂux in the kidney and permeability-limited uptake in the
liver based on available in vitro and in vivo data. A novel feature of the
ﬁnal model for metformin was the incorporation of an electrochemical
driving force for uptake by OCT1 and OCT2.
2. Material and methods
Full PBPK models were developed for metformin and cimetidine in
the Simcyp Simulator® Version 14 (Simcyp Ltd., A Certara Company,
Shefﬁeld, UK) (Fig. 1). For metformin, renal and hepatic disposition
were described by a mechanistic kidney model (Mech KiM) (Neuhoff
et al., 2013a) and a permeability-limited liver model (PerL) (Jamei
et al., 2014; Neuhoff et al., 2013b), respectively. For cimetidine, renal
disposition was described by Mech KiM. For both compounds, distribu-
tion to all other organs was assumed to be perfusion-limited, with
tissue-to-plasma partition coefﬁcients (Kp's) predicted using the meth-
od of Rodgers et al. (Jamei et al., 2014; Rodgers and Rowland, 2007). A
schematic representation of the processes governing the renal secretion
of metformin and cimetidine in the proximal tubule of the kidney is
shown in Fig. 2.
2.1. Model development
2.1.1. Metformin
Data used in the development of the metformin model are
summarised in Table 1. Where these data were obtained from morethan one study, weighted mean values were calculated based on the
number of observations in each study. Absorption following an oral
dose of metformin was described as a ﬁrst-order process after a lag
time (tlag) with a mean fraction absorbed (fa) of 0.7 (Pentikainen
et al., 1979; Tucker et al., 1981). Estimates of kawere obtained by ﬁtting
a one-compartment PK model to mean plasma metformin concentra-
tions reported after administration of 500 to 1500 mg immediate re-
lease tablets using Phoenix® WinNonlin® software (Version 6.3,
Pharsight, A Certara Company). Aweightedmean value of kawas deter-
mined based on the number of individuals in each study.
Total metabolic clearance in the liver was incorporated in themodel
based on back calculation of intrinsic metabolic clearance from the total
blood clearance after an intravenous dose (32.0 L·h−1) after subtraction
of renal clearance with respect to blood (26.1 L·h−1), using themethod
described by Jamei et al. (2014) (Jamei et al., 2014; Pentikainen et al.,
1979; Sirtori et al., 1978; Tucker et al., 1981). A ﬁxed average blood-
to-plasma ratio of metformin was determined from paired AUC values
in blood and plasma after intravenous and oral dosing (Robert et al.,
2003; Sambol et al., 1995; Tucker et al., 1981).
The steady state volume of distribution of metformin (Vss) was pre-
dicted using the method of Rodgers and Rowland (2007).
Data describing the OCT2, MATE1 andMATE2-Kmediated transport
of metformin were obtained from a study using transfected HEK293
cells (Ito et al., 2012). Rates of transport were extracted from Eadie–
Hoftsee plots and converted from units of μL·min−1·mg protein−1 to
μL·min−1·106 cells−1 on the basis that 1 million HEK293 cells contain
0.93 mg of total protein (Lazorova, 2010). Estimates of the maximum
rate of active transport (Jmax), Michaelis constant (Km) and the passive
permeability-surface area product (CLPD) were obtained by nonlinear
least squares regression using Equation 1. As saturation of transport
was not observed at therapeutic concentrations (Km N 300 μM in all
cases) intrinsic clearances (μL·min−1·106 PTC−1) for OCT2 uptake
and the sum of MATE1 and MATE2-K (MATE1/2-K) efﬂux were applied
in Mech KiM.
uptake rate ¼ J max∙ S½ 
Km þ S½  þ CLPD∙ S½  ð1Þ
where the rate of uptake is in units of pmol·min−1·106 cells−1, [S] is
the substrate concentration (μM), Jmax is the maximum rate of active
transport (pmol·min−1·106 cells−1), Km is the Michaelis constant
(μM) and CLPD is the passive permeability-surface area product
(μL·min−1·106 cells−1).
The passive permeability of metformin in the kidney (CLPD,kidney)
was obtained by multiplying permeability in a PAMPA system
(5 × 10−7 cm·s−1 (Balimane and Chong, 2008)) by an estimated total
nephron surface area. In Mech KiM, the lengths and diameters of the
proximal tubule, loop of Henle, distal tubule and collecting duct are de-
ﬁned for a typical nephron (Neuhoff et al., 2013a). From these, the sur-
face area of a single nephron was calculated and scaled to a total
nephron surface area of 291 cm2 based on the number of nephrons
(1.6×106) in a representative healthy Caucasian (Neuhoff et al., 2013a).
Hepatic uptake by OCT1 and passive permeability in the liver were
applied in the PerL model using estimates of intrinsic clearance and
CLPD,liver, respectively, fromexperimentswith cryopreserved humanhe-
patocytes (Sogame et al., 2009).
To account for discrepancies in both transporter expression and ac-
tivity between in vitro transfection systems and in vivo proximal tubule
cells/hepatocytes, relative activity factors (RAFs) were estimated as sca-
lars for each active transport process (Harwood et al., 2013). Currently,
experimental RAF values for the relevant transporters are not available.
Therefore, operational values were determined by ﬁtting a training set
of mean plasma drug concentration-time and urinary excretion data
collated from one study in which a 250 mg intravenous bolus dose of
metformin was administered (Tucker et al., 1981) and three studies in
which 500 mg oral doses (Caille et al., 1993; Karttunen et al., 1983;
Fig. 1. Structure of a general PBPK model used to describe the kinetics of metformin and cimetidine (centre) and associated nested permeability-limited liver (PerL, left) and mechanistic kidney (Mech KiM, right) models.
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Fig. 2. A schematic representation of transport processes for metformin and cimetidine and their interaction in renal proximal tubule cells.
73H.J. Burt et al. / European Journal of Pharmaceutical Sciences 88 (2016) 70–82Sambol et al., 1996a) were given. RAF values were determined sequen-
tially for each transporter and, in each case, studies were ﬁtted individ-
ually and a mean RAF was applied in the model. Firstly, a RAF value for
OCT1 transport in the liver was determined by ﬁtting the in vivo plasmaTable 1
Parameter values used to construct the PBPK model for metformin.
Parameter Value (%CV) Source
Physchem and blood binding
Molecular weight 129.16
Compound type Monoprotic base
pKa 11.8 Avdeef (2012), Ray (1961)
LogP −1.43 Schafer and Bojanowski, (1972)
fu 1 Tucker et al. (1981)
B/P 1 Robert et al. (2003), Sambol et al. (199
Absorption
ka (h−1) 0.27 (30) Caille et al. (1993), Chen et al. (2009);
(1996a), Sambol et al. (1995), Sambol e
tlag (h) 0.29 (56) Tucker et al. (1981)
fa 0.7 (16) Pentikainen et al. (1979), Tucker et al. (
Distribution
Model Full PBPK
Vss (L/kg) 0.99
Transport-kidney
Model Mech KiM
OCT2 CLint (μL·min−1·106
PTC−1)
14.2 Ito et al. (2012)
OCT2 RAF 3
MATE1/MATE2-K CLint
(μL·min−1·106 PTC−1)
16.6 Ito et al. (2012)
MATE1/MATE2-K RAF 3
CLPD,kidney (mL·min−1.106
PTC−1)
4.26 × 10−7 Balimane and Chong (2008)
fukidney cell 1
Transport-liver
Model PerL
OCT1 CLint (μL·min−1·106
hepatocytes−1)
0.316 Sogame et al. (2009)
OCT1 RAF 3
CLPD,liver (mL·min−1·106
hepatocytes−1)
5.88 × 10−5 Sogame et al. (2009)
fuhepatocyte 1
Metabolism
HLM CLint (μL·min−1·mg
protein−1)
1.62 Pentikainen et al. (1979), Sirtori et al. (data using the parameter estimationmodulewithin the Simcyp Simula-
tor (weighted least squares ﬁtting, weighted by the reciprocal of the
predicted value squared), while ﬁxing metformin renal clearance at
the observed mean value of 26.1 L·h−1 (Pentikainen et al., 1979;Comments
Measured
Measured
Measured
5), Tucker et al. (1981) Calculated from AUCblood/AUCplasma
Pentikainen et al. (1979), Sambol et al.
t al. (1996b)
Fitted
Fitted
1981) Value from in vivo data
Predicted — Rodgers and Rowland method
(Rodgers and Rowland, 2007)
Measured-transfected HEK293
Fitted
Measured-transfected HEK293
Fitted
Scaled PAMPA permeability
Predicted — Rodgers and Rowland method
(Rodgers and Rowland, 2007)
Measured — cryopreserved hepatocytes
Fitted
Measured — cryopreserved hepatocytes
Predicted — Rodgers and Rowland method
(Rodgers and Rowland, 2007)
1978), Tucker et al. (1981) Retrograde calculation
74 H.J. Burt et al. / European Journal of Pharmaceutical Sciences 88 (2016) 70–82Sirtori et al., 1978; Tucker et al., 1981). Secondly, using Mech KiM and
the resulting hepatic OCT1 RAF, the RAF for OCT2 uptake in the kidney
was obtained by ﬁtting of the plasmametformin concentration data. Fi-
nally, a RAF value for MATE1/2-K efﬂux in the kidney was obtained by
sensitivity analysis of the urinary excretion data.
2.1.2. Cimetidine
Data used in the development of the cimetidine model are
summarised in Table 2. Absorption following an oral dose of cimetidine
was described by a ﬁrst-order process after a lag time (tlag). Estimates
for ka and tlag were obtained by ﬁtting plasma cimetidine drug
concentration-time proﬁles reported after the administration of
400 mg cimetidine as immediate release tablets (Grahnen et al., 1979;
Gugler et al., 1981a; Somogyi et al., 1981) with the cimetidine PBPK
model using the parameter estimation module within the Simcyp Sim-
ulator (weighted least squares ﬁtting, weighted by the reciprocal of the
predicted value squared). Total metabolic clearance in the liver was in-
corporated in themodel by back-calculation of intrinsicmetabolic clear-
ance from total blood clearance following an intravenous dose (41.0 L/Table 2
Parameter values used to construct the PBPK model for cimetidine.
Parameter Value (%CV) Source
Physchem and blood
binding
Molecular weight 252.34
Compound type Monoprotic base
pKa 6.9 Avdeef and Berger (2001), Durant et al. (
LogP 0.48 Avdeef and Berger (2001)
fu 0.8 Somogyi et al. (1980), Taylor et al. (1978
B/P 0.97 Somogyi et al. (1980)
Absorption
ka (h−1) 0.7 (18) Grahnen et al. (1979), Gugler et al. (1981
tlag (h) 0.15 (28) Grahnen et al. (1979), Gugler et al. (1981
fa 0.92 (30) Gugler et al. (1981b), Taylor et al. (1978)
Distribution
Model Full PBPK
Vss (L/kg) 0.60
Transport-kidney
Model Mech KiM
OCT2 Jmax
(pmol·min−1·106
PTC−1)
2170 Tahara et al. (2005)
OCT2 Km (μM) 72.6 Tahara et al. (2005)
OCT2 RAF 3
OAT3 Jmax
(pmol·min−1·106
PTC−1)
1232 Erdman et al. (2006), Tahara et al. (2005
OAT3 Km (μM) 161.5 Erdman et al. (2006), Tahara et al. (2005
OAT3 RAF 3
MATE1 Jmax
(pmol·min−1·106
PTC−1)
135.5 Matsumoto et al. (2008), Ohta et al. (200
MATE1 Km (μM) 7.7 Matsumoto et al. (2008), Ohta et al. (200
MATE1 RAF 3
MATE2-K Jmax
(pmol·min−1·106
PTC−1)
216 Ohta et al. (2009)
MATE2-K Km (μM) 18.2 Ohta et al. (2009)
MATE2-K RAF 3
OCT1 Ki (μM) 104 Ito et al. (2012)
OCT2 Ki (μM) 124 Ito et al. (2012)
MATE1/MATE2-K Ki
(μM)
5.4 Ito et al. (2012)
CLPD,kidney
(mL·min−1·106 PTC−1)
2.61 × 10−5 Balimane and Chong, (2008)
fukidney cell 1
Metabolism
HLM CLint
(μL·min−1·mg
protein−1)
2.87 Grahnen et al. (1979), Lebert et al. (1981
Villeneuve et al. (1983), Walkenstein et ah) after subtraction of renal clearance with respect to blood (32.6 L/h),
using the retrograde calculation method described by Jamei et al.
(2014) (Grahnen et al., 1979; Jamei et al., 2014; Lebert et al., 1981;
Somogyi and Gugler, 1985; Villeneuve et al., 1983; Walkenstein et al.,
1978).
The volume of distribution of cimetidine (Vss) was predicted using
the method of Rodgers and Rowland (2007).
Data describing theOAT3, OCT2,MATE1 andMATE2-Kmediated up-
take of cimetidine were obtained from studies using transfected
HEK293 cells (Erdman et al., 2006; Ito et al., 2012; Matsumoto et al.,
2008; Ohta et al., 2009; Tahara et al., 2005). In addition, Ki values for
OCT1, OCT2, MATE1 and MATE2-K inhibitions by cimetidine in
HEK293 cells were utilised to predict the interaction with metformin
(Ito et al., 2012). As the Ki values for MATE1 and MATE2-K were within
1.8-fold of each other, an average value was applied with respect to a
combined metformin MATE1/2-K intrinsic clearance (Ito et al., 2012).
The CLPD,kidney of cimetidine applied within Mech KiM was obtained
by multiplying Caco-2 permeability (3 × 10−5 cm·s−1 (Balimane and
Chong, 2008)) by the total nephron surface area as described forComments
1977) Measured
Measured
) Measured
Measured
a), Somogyi et al. (1981) Fitted
a), Somogyi et al. (1981) Fitted
Value from in vivo data
Predicted — Rodgers and Rowland method
(Rodgers and Rowland, 2007)
Measured — transfected HEK293
Measured — transfected HEK293
Same as value for metformin
) Measured — transfected HEK293
) Measured — transfected HEK293
Same as value for metformin
9) Measured – transfected HEK293
9) Measured — transfected HEK293
Same as value for metformin
Measured — transfected HEK293
Measured — transfected HEK293
Same as value for metformin
Measured — transfected HEK293
Measured — transfected HEK293
Measured — mean of MATE1 and MATE2K
Scaled from Caco-2 permeability
Predicted — Rodgers and Rowland method
(Rodgers and Rowland, 2007)
), Somogyi and Gugler (1985),
l. (1978)
Retrograde calculation
75H.J. Burt et al. / European Journal of Pharmaceutical Sciences 88 (2016) 70–82metformin. The operational RAF values estimated for metformin were
also applied for cimetidine. This was done on the basis that the param-
eters describing the OCT2/MATE transport of cimetidine andmetformin
were both derived from studies with transfected HEK293 cells and in 3
out of 4 cases the cimetidine in vitro data were obtained from the same
laboratory.With respect to theOAT3 RAF for cimetidine, the assumption
wasmade that the similarity in the determined RAF values for OCT2 and
MATEs in transfected HEK293 cells extended to this transporter.
2.2. Model veriﬁcation
The performance of themetformin and cimetidine PBPKmodels was
evaluated by comparing simulated plasma drug concentrations and uri-
nary excretion rates with those observed in a test set of studies not used
to build themodel. Formetformin, its kinetics after single 500–1500mg
oral doses and 500mg BID oral doses was simulated (Balan et al., 2001;
Gusler et al., 2001; Karttunen et al., 1983; Pentikainen, 1986; Scheen
et al., 1994; Tucker et al., 1981; Tzvetkov et al., 2009). For cimetidine,
its kinetics after single 300 mg oral doses and multiple 400 mg BID
and TID oral doses was simulated (Kirch et al., 1989; Muirhead et al.,
1986; Somogyi et al., 1987; Walkenstein et al., 1978). Data from two
studies involving the co-administration of metformin (250 mg QD and
500 mg single dose) and cimetidine (400 mg BID) were also simulated
(Somogyi et al., 1987; Wang et al., 2008). For each study, ten trials
were simulated in which the number, age range and gender of the vir-
tual subjects were matched to those of the real subjects. The ‘Sim-
Healthy Volunteer’ population library was used to simulate trials con-
ducted in healthy Caucasian subjects and the ‘Chinese-Healthy Volun-
teer’ population library was used to simulate the DDI study of Wang
et al., 2008. In the latter study, mean plasma metformin concentrations
and PK parameters were reported for different genotypes of the OCT2
808G N T variant. In this case, population mean values were generated
using the expected number of individuals with each genotype, based
on the allele frequency reported in the study and assuming Hardy–
Weinberg equilibrium.
A sensitivity analysis was performed to investigate the impact of de-
creasing the cimetidine Ki values for OCT1, OCT2 andMATE1/2-K deter-
mined in vitro. This was done using a single virtual healthy subject with
the mean attributes of the Caucasian population.
2.3. Model reﬁnement
An alternative description ofmetformin transport byOCT1 andOCT2
was devised, accounting for modulation of these processes by an elec-
trochemical driving force (Φdf). As the intracellular to extracellular
drug concentration ratio increases, this electrochemical driving force
decreases, thereby placing a feedback limit on the extent of intracellular
accumulation. In the ﬁrst instance, the data of Kimura et al. (2005) and
Nies et al. (2011) on the uptake of metformin into HEK293 cells
transfected with OCT2 and OCT1, respectively, were ﬁtted by a two
compartment model deﬁning drug concentration in the incubationme-
dium (Equation 2) and in the cells (Equation 3), using the R program-
ming language (Version 3.0.1, R Foundation for Statistical Computing).
Φdf is deﬁned as the difference between the membrane potential
(Φm) and the ion equilibrium potential described by the Nernst equa-
tion (Equation 4). It has a negative valuewhen conditions favour theup-
take of metformin into the cell. Passive transcellular movement of
metforminwas assumed to be negligible on the basis of negligible accu-
mulation in non-transfected HEK293 cells.
Vmed∙
d S½ med
dt
¼ Φdf ∙ JOCT ∙No:cells ð2Þ
Vcell∙No:cells∙
d S½ cell
dt
¼ Φdf ∙ JOCT ∙No:cells ð3Þwhere [S]med and [S]cell are the substrate concentrations (μM) in medi-
um and cells, respectively; Vmed and Vcell are the volume (μL) of theme-
dium and cells (per 106 cells), respectively; JOCT is the rate
(pmol·min−1·volt−1·106 cells−1) of OCT1 or OCT2 mediated trans-
port; No. cells is the number of cells (106 cells) in the monolayer and
Φdf is the electrochemical driving force (volts).
Φdf ¼ Φm 
R∙T
z∙F
∙ ln
S½ med∙fumed
S½ cell∙fucell
 
ð4Þ
whereΦm is themembrane potential (volts), R is the universal gas con-
stant (8.314 J.K−1·mol−1), T is temperature (310.15 K in the experi-
ment at 37 °C), z is the valence of the ionic species (1 for metformin),
F is Faraday's constant (96,490 C·mol−1) and fumed and fucell are the
fractions of metformin unbound in media and cells, respectively (both
assumed to be 1).
The number of cells in the HEK293-OCT2 and HEK293-OCT1 mono-
layers were estimated to be 1.73 × 106 and 1.68 × 106, respectively,
based on the seeding densities and the growth rate of HEK293 mono-
layers over the culture period (Park et al., 2004). A HEK293 cell volume
of 6.4 μL/mg protein was used (Gillen and Forbush, 1999; Tamai et al.,
1997). This equates to a total cell volumes (Vcell) of 10.2 μL and 10.1 μL
for the HEK293-OCT2 and HEK293-OCT1 monolayers, respectively,
given that 1 million HEK293 cells contain 0.93 mg of total protein
(Lazorova, 2010). A Φm value of−35 mV was used based on data ob-
tained with non-transfected HEK293 cells (Chemin et al., 2000).
With all other parameters ﬁxed, the value of JOCT was determined by
weighted (1/Y2) least squares regression using the ‘optim’ function (L-
BFGS-Bmethod) in R. A corresponding value of CLint,OCT2 based on a con-
ventional uptake function was determined by ﬁtting Equations 5 and 6.
Vmed∙
d S½ med
dt
¼ CLint;OCT ∙No:cells∙ S½ med∙fumed ð5Þ
Vcell∙No:cells∙
d S½ cell
dt
¼ CLint;OCT ∙No:cells∙ S½ med∙fumed ð6Þ
where CLint,OCT is the intrinsic clearance (μL·min−1·106 cells−1) for OCT
mediated transport.
The impact of incorporating the electrogenic OCT1 and OCT2 trans-
port models into the PBPK model for metformin was evaluated. For
this purpose, the previously described PBPK models for metformin
and cimetidine were recreated in Simulink (Version 8.1; MathWorks,
Inc., Natick, MA) with the rate of OCT1 mediated uptake of metformin
from extracellular water into hepatocytes deﬁned either by Equation 7
(conventional model) or Equations 9 and 10 (electrogenic model) and
the rate of OCT2 mediated uptake of metformin from blood into proxi-
mal tubule cells deﬁned either by Equation 8 (conventional model) or
Equations 11 and 12 (electrogenic model). The relevant JOCT for use
with the electrogenic model was the value obtained by ﬁtting the
in vitro data.
rate of OCT1 uptake
¼ Metformin½ EW;u∙
CLint;OCT1
1þ Cimetidine½ B;u
Ki;OCT1
∙RAF∙HPGL∙LW∙60=106 ð7Þ
where the rate of OCT1 uptake is the value for the whole liver (μmol/h);
CLint,OCT1 is the in vitro intrinsic clearance for OCT1 uptake
(μL·min−1·106 cells−1); [Metformin]EW,u and [Cimetidine]B,u are the
unbound concentrations of metformin and cimetidine, respectively in
hepatic extracellular water and blood (μM); Ki,OCT1 is the cimetidine
OCT1 inhibition constant (μM); HPGL is hepatocytes per gram of liver
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rate of OCT2 uptake
¼ Metformin½ PT;B;u∙
CLint;OCT2
1þ Cimetidine½ PT;B;u
Ki;OCT2
∙RAF∙PTCPGK ∙KW ∙60=106 ð8Þ
where the rate of OCT2 uptake is the value for both kidneys (μmol/h);
CLint,OCT2 is the in vitro intrinsic clearance for OCT2 uptake
(μL·min−1·106 cells−1); [Metformin]PT,B,u and [Cimetidine]PT,B,u are
the unbound concentrations of metformin and cimetidine, respectively
in proximal tubule blood (μM); Ki,OCT2 is the cimetidine OCT2 inhibition
constant (μM); PTCPGK is proximal tubule cells per gram of kidney
(106 cells) and KW is the weight of both kidneys (grams).
rate of OCT1 uptake
¼ Φdf ∙
JOCT1
1þ Cimetidine½ B;u
Ki;OCT1
∙RAF∙HPGL∙LW∙60=106 ð9Þ
Φdf ¼ Φm 
R∙T
z∙F
∙ ln
Metformin½ EW;u
Metformin½ IW;u
 !
ð10Þ
where JOCT2 is the in vitro rate ofOCT1uptake (pmol·min−1·volt−1·106 cells−1)
and [Metformin]IW,u is the unbound concentration of metformin in in-
tracellular water of hepatocytes. A Φm for hepatocytes of−35 mV was
used (Veech et al., 1995).
rate of OCT2 uptake
¼ Φdf ∙
JOCT2
1þ Cimetidine½ PT;B;u
Ki;OCT2
∙RAF∙PTCPGK ∙KW ∙60=106 ð11ÞFig. 3. Comparison ofmean simulated plasmametformin concentrations (black line) and observ
Tzvetkov et al., 2009), (B) 500mg BID dosing (Ο=Karttunen et al., 1983). (C) Comparison ofm
data after a single 500 mg dose (X=Tucker et al., 1981, Ο=Karttunen et al., 1983). Grey lines
trials) (—) and observed (Ο) meanmetformin single dose AUC values. PK studies: 1 and 7, (Tuc
(Pentikainen, 1986); 6, (Scheen et al., 1994); 8, (Karttunen et al., 1983).Φdf ¼ Φm 
R∙T
z∙F
∙ ln
Metformin½ PT;B∙
fu
B=P
Metformin½ PT;cell∙fukidneycell
0
BB@
1
CCA ð12Þ
where JOCT2 is the in vitro rate of OCT2 uptake (pmol·min−1·volt−1·106-
cells−1) and fukidney cell is the free fraction of drug in the kidney cell. A
Φm for proximal tubule cells of−60 mV was used (Pelis and Wright,
2011).
Following the incorporation of the electrogenic equations into the
PBPK model for metformin, the RAF values for OCT1, OCT2 and MATEs
were simultaneously re-optimised using plasma and urinary excretion
data from the metformin training dataset described previously. This
model was used to simulate the effects of cimetidine (400 mg BID) on
metformin (250 mg QD and 500 mg single dose) kinetics reported in
the two DDI studies (Somogyi et al., 1987; Wang et al., 2008). A single
virtual individualwas usedwith themean attributes of the healthy Cau-
casian (Somogyi et al., 1987) or Chinese (Wang et al., 2008) populations
within the Simcyp Simulator.
3. Results
3.1. Initial model
A RAF of 3 for hepatic OCT1 uptake transport was determined on
ﬁtting themetformin training data. As expected, the scaled passive per-
meability of metformin across the apical and basal membranes of renal
cells was negligible (CLPD = 4.26 × 10−7 mL·min−1·106 PTC−1). This,
combined with the fact that transporter mediated uptake and efﬂux
were deﬁned as unidirectional processes in the conventional model,
meant that MATE1/2-K efﬂux had negligible impact on simulated plas-
mametformin concentrations. On this basis, plasmametformin concen-
trationswere used to deﬁne a suitable value for the RAF for OCT2uptakeed data after (A) a single 500mgdose (X=Tucker et al., 1981,Δ=Gusler et al., 2001,Ο=
ean simulated urinary recovery of unchangedmetformin in urine (black line) and observed
represent the mean data for each of 10 simulated trials. (D) Comparison of simulated (10
ker et al., 1981); 2, (Gusler et al., 2001); 3, (Tzvetkov et al., 2009); 4, (Balan et al., 2001); 5,
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value for MATE1/2-K efﬂux. RAF values of 3 were determined for both
metformin renal OCT2 uptake and MATE1/2-K efﬂux.
Simulated mean plasma metformin concentrations after single and
BID oral doses of 500mgmetformin HCl andmean plasma AUC after sin-
gle 500 to 1500 mg doses were consistent with observed values (Fig. 3A,
B and D). Simulated mean Cmax values were in agreement with observed
values for 6 out of 7 studies, while simulated tmax values of 2 to 3 h were
within 1 h of observed mean values (Supplementary Fig. 1). Simulated
urinary recoveries of metformin were consistent with observed values,
when the dose of freemetformin base, bioavailability and fraction excret-
ed in urinewere considered (Fig. 3C). The simulatedmean bioavailability
and renal clearance values of 0.62 ± 0.10 and 32.0 ± 9.0 L·h−1 (SD) in
healthy subjects were consistent with observed values (Graham et al.,
2011). The standard deviations of AUC, Cmax, tmax and urinary recovery
values from the simulated trials were consistent with observed values
in 100, 67, 40 and 80% of cases, respectively (Supplementary Fig. 2).
Simulated mean plasma cimetidine concentrations after a single
300 mg oral dose only matched observed values from 3 h (Walkenstein
et al., 1978); at earlier time points some individual proﬁles showed dou-
ble peaks that were not recovered by the ﬁrst-order absorption function
(Fig. 4A). Nevertheless, the simulated mean (SD) AUC(0, 12 h) of 5.8 ±
1.5 mg·L−1·h (SD) was comparable to the observed value of 5.0 ±
1 mg·L−1·h (SD). Simulated mean plasma cimetidine concentrations
during administration of 400 mg BID (Muirhead et al., 1986; Somogyi
et al., 1981) and TID (Kirch et al., 1989) were consistent with observed
values (Fig. 4B–C). The range of simulated urinary recoveries of un-
changed cimetidine at 300mg SD and 400mg BID captured the observed
values. However, an overprediction of the urinary recovery of cimetidine
was evident at the 400 mg TID dose (Fig. 4D).Fig. 4. Comparison of simulated and observed (A) plasma cimetidine concentrations after a s
respectively, Ο and grey dots represent mean and individual data, respectively, fromWalken
and grey lines represent simulated overall and trial means, respectively, (X = Somogyi et a
represent simulated overall and trial means, respectively, (Δ= Kirch et al., 1989). Comparis
urinary recovery of unchanged cimetidine (D). PK studies: 1, (Walkenstein et al., 1978); 2, (MIn the absence of cimetidine, the simulatedmean plasmametformin
AUC (0,24 h) of 7.1 mg·L−1·h (single 500 mg dose) was within 10% of
the value of 6.6 mg·L−1.h observed by Wang et al. (2008); it was
3.3 mg·L−1·h (250mg QD) compared to the value of 4.3 mg·L−1.h ob-
served by Somogyi et al. (1987). In part, the latter discrepancy may be
related to the inclusion in the study of Somogyi et al. of 2 subjects out
of the 7 with GFR values of less than 40 mL·min−1. In the presence of
cimetidine (400 mg BID), observed increases in metformin AUC and
Cmax values were 1.46- and 1.73-fold (Somogyi et al., 1987) and 1.46-
and 1.40-fold (Wang et al., 2008), but the model predicted no change.
While Somogyi et al. observed a non-signiﬁcant 4% increase in the uri-
nary recovery of metformin when co-administered with cimetidine,
Wang et al. reported an overall 21% decrease (albeit not signiﬁcant for
OCT1 homozygous wild-type subjects). The model predicted no change
in the urinary recovery of metformin in the presence of cimetidine.
Using a trial design matched to that of Somogyi et al. (1987), sensi-
tivity analysis indicated that the observed metformin plasma AUC ratio
could only be recovered when the cimetidine Ki value for OCT2was de-
creased 1000-fold from the value of 124 μM observed in vitro (Ito et al.,
2012). This was accompanied by a predicted decrease in the metformin
concentration ratio (DDI/control) in the cells of the ﬁrst segment of the
proximal tubule from 1.8 to 0.6 but little change in the urinary recovery
of unchanged metformin (Fig. 5A). Decreasing the cimetidine Ki for
MATE1/2-K from the value determined in vitro of 5.4 μM had negligible
impact onmetformin plasma AUC and urinary recovery ratios although,
as expected, metformin concentrations in the ﬁrst segment of the prox-
imal tubule were very sensitive to this parameter (Fig. 5B). The effect of
decreasing the cimetidine Ki for OCT1 from its in vitro value of 104 μM
on the metformin plasma AUC ratio was minimal, whereas simulta-
neously decreasing the cimetidine Ki values for OCT1 and OCT2 byingle 300 mg dose (black and grey lines represent simulated mean and 95th percentiles,
stein et al. (1978), (B) plasma cimetidine concentrations after 400 mg BID dosing (black
l., 1987, □= Muirhead et al., 1986), and (C) 400 mg TID dosing (black and grey lines
on of simulated (10 trials) (—) and observed (Ο) mean cimetidine AUC values (C) and
uirhead et al., 1986); 3, (Somogyi et al., 1987); 4, (Kirch et al., 1989).
Fig. 5. Sensitivity of ratios (DDI/control) ofmetformin (Ο) plasma AUC, (□) proximal tubule cell segment 1 AUC and (X) urinary recovery to cimetidine Ki values for (A) OCT2, (B)MATE1/
2-K and (C) both OCT1 and OCT2 based on a PBPK model incorporating a conventional description of transport kinetics for both drugs.
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ratio.3.2. Model reﬁnement
The electrogenic model of the transport of metformin by OCT2 was
superior to the conventional model in describing uptake in transfected
HEK293 cells, with a resulting JOCT2 estimate (SE) of 1155 ±
158 pmol·min−1·volt−1·106 cells−1 (Fig. 6A). The corresponding
model for OCT1 transport was able to recover the metformin uptake
in transfected HEK293 cells reasonably well, with a JOCT1estimate (SE)
of 27.5 ± 5.0 pmol·min−1·volt−1·106 cells−1 (Fig. 6B). However, in
this case, the model did not provide an improvement over the conven-
tional model.
Following the introduction of electrogenic functions for hepatic
OCT1 transport and renal OCT2 transport into the metformin PBPK
model, RAFs of 1.1, 2.3 and 1.0 were determined for OCT1, OCT2 and
MATEs, respectively. While the incorporation of electrogenic OCT1 and
OCT2 transport did not change the simulation of plasma drug concen-
trations in the absence of cimetidine, it did introduce sensitivity to
MATE1/2-K inhibition (Fig. 7). To recover the full extent of the change
in the plasma AUC of metformin in the presence of cimetidine it was
necessary to invoke a 12-fold decrease in the cimetidine Ki for MATE1/
2-K or a combined 8-fold decrease in the Ki's for OCT1, OCT2 and
MATE1/2-K (Somogyi et al., 1987 data, Fig. 8A). The corresponding de-
crease in Ki's for OCT1, OCT2 and MATE1/2-K necessary to recover the
observations fromWang et al. (2008)was 18-fold (Fig. 8B). The correla-
tion of observed and simulated plasma metformin concentrations withFig. 6. Comparison of the ability of a conventional model (dashed lines) and an electrogenic mo
(A) hOCT2 transfected HEK293 cells, (Kimura et al., 2005) or (B) hOCT1 transfected HEK293 cthe initial and ﬁnal models is provided in Supplementary Figs. 3 and 4,
respectively.
4. Discussion
Incorporation of permeability-limited hepatic uptake by OCT1 and
active renal transport by OCT2 and MATEs into a PBPK model allowed
the simulation of plasma concentrations and urinary excretion of met-
formin when given alone. However, complete development of this
PBPK model from the ‘bottom up’ was not possible, particularly in the
absence of robust in vitro and in vivo abundance data for the relevant
transporters. Therefore, it was necessary to ﬁt in vivo data formetformin
to derive net transporter scalars (RAFs). The RAF of 3 for OCT1, OCT2 and
MATE transport that was determinedwith the original metformin PBPK
model compares to a value of 5.3 reported by Posada et al. (2015) for
OAT3 mediated renal uptake of pemetrexed based on HEK293 cell
data using a similar approach. A further issuewith respect tometformin
relates to its low passive permeability. While active uptake was
assigned to the liver and the kidney, it was assumed that distribution
into all other tissues was perfusion-limited. A marked time-
dependence in the value of the blood/plasma concentration ratio of
metformin, ranging from 0.5 at early times to 6 at later times in a repre-
sentative subject after oral dosing (Tucker et al., 1981), indicates that
general cellular penetration is slow or that uptake transporters operate
more widely with respect to net distribution. In modelling the kinetics
of metformin an average blood/plasma concentration ratio was used
based on relative blood-to-plasma AUC values. Xie et al. (2015) recently
reported a PBPK model for metformin in which the incorporation of
plasma - blood cell distribution rate constants allowed recovery ofdel (solid line) to describe experimental data (open circles) on the uptake of metformin by
ells, (Nies et al., 2011).
Fig. 7. Sensitivity of ratios (DDI/control) of metformin (Ο) plasma AUC, (□) proximal tubule cell segment 1 AUC and (X) urinary recovery to in cimetidine Ki for (A) MATE1/2-K and
(B) OCT1, OCT2 and MATE1/2-K based on a PBPK model incorporating an electrochemical description of metformin OCT2 transport.
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time. When a blood cell distribution compartment was incorporated
into themetformin PBPKmodel of the current study (using a similar ap-
proach to Xie et al.), simulated plasma metformin concentrations and
the extent of the DDI with cimetidine were unaffected (data not
shown). Therefore the approximation to an average blood/plasma con-
centration ratio used in the original model is not considered to detract
from the main ﬁndings of this modelling exercise. In vivo data indicate
that the oral absorption of metformin shows a degree of saturability
(Proctor et al., 2008; Tucker et al., 1981). This would be consistent
with the suggestion that the drug is subject to PMAT, OCT1 and OCT3
mediated uptake on the apical membrane of enterocytes, and that
there is interplay between these uptake transporters and paracellular
absorption (Proctor et al., 2008; Zhou et al., 2007). Although the PBPK
model developed for metformin did not incorporate a saturable,
transport-mediated component to oral absorption, it was able to recov-
er plasma drug concentrations over the 500–1500 mg oral dose range
with reasonable accuracy.
To simulate the effect of co-administration of cimetidine acting as an
inhibitor of MATE and OCT transporters (Fig. 2), it was necessary to re-
ﬁne the original metformin PBPKmodel by introducing electrochemical
modulation of OCT1 and OCT2 transport. In vitro studies have reported
cimetidine Ki values between 21 and 94-fold lower for the inhibition
of MATEs compared to OCTs, concluding that the inhibition of OCTs by
cimetidine is unlikely at therapeutic doses (Ito et al., 2012; Tsuda
et al., 2009). However, the conventional model of OCT transport is uni-
directional and insensitive to intracellular substrate concentrations, and
transcellular passive permeability ofmetformin is considered to be neg-
ligible. Under these conditions, inhibition of MATE1/2-K mediatedFig. 8. Comparison of observedmean plasmametformin concentrationswith (ﬁlled circles) and
(B) Wang et al. (2008) and corresponding simulated data with (solid line) and without (das
representative individual using the electrogenic OCT2 model and with cimetidine Ki's for OCT1metformin efﬂux in the proximal tubule by cimetidine had no effect
on simulated plasmametformin concentrations, despite a signiﬁcant in-
crease in drug concentration within the proximal tubule cells (Fig. 5B).
This was clearly inconsistent with the observed 46% increase in plasma
metformin AUC (Somogyi et al., 1987; Wang et al., 2008).
The OCTs function as electrogenic transporters, with both mem-
brane potential and the substrate concentration gradient across the
membrane providing the driving force for transport (Koepsell et al.,
2007; Pelis and Wright, 2011). This combined electrochemical driving
force allows a higher concentration of cations on one side of a mem-
brane as they move down their electrochemical gradients, to a point
that can be deﬁned by their Nernst potentials. Data from rats indicate
that Oct2 functions as a cation uniporter at low substrate concentra-
tions, but as an electroneutral cation exchanger at high substrate con-
centrations on both sides of the membrane (Koepsell, 2011). Although
well-known as a determinant of passive ion transport (Barts and
Borst-Pauwels, 1985; Stein, 1977), this phenomenon is not accounted
for in conventional models applied to the OCT mediated transport of
drugs. In these conventional models, the rate of drug transport is de-
ﬁned as a ﬁrst order process (Hsu et al., 2014) or by aMichaelis–Menten
functionwhen saturation is observed at higher substrate concentrations
(Jamei et al., 2014; Neuhoff et al., 2013b). Although such models ade-
quately describe the uptake of metformin in vitro, in which experiments
are usually conducted over a time-course of several minutes, PBPK
model simulations are applied over a signiﬁcantly longer time-course
of hours or days, requiring that the full impact of intracellular accumu-
lation on OCT uptake be accounted for.
In the current study, the application of functions describing
electrochemically-mediated OCT2 transport was able to account for awithout (open circles) co-administration of cimetidine from (A) Somogyi et al. (1987) and
hed line) co-administration of cimetidine. Simulations were performed for a population
, OCT2 and MATE1/2-K decreased by 8 and 16-fold from those determined in vitro.
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transfected HEK293 cells as its intracellular concentration increased,
relative to that predicted by a conventional model. Incorporation of
electrogenicmodels for OCT1 andOCT2 transport within themetformin
PBPKmodel rendered the plasma concentrations of the drug sensitive to
inhibition of renal MATE1/2-K by cimetidine, as the simulated increase
in intracellular metformin concentrations led to a knock-on reduction
in the OCT2 driving force. In combination with 8 to 18-fold decreases
in the cimetidineKi values for the relevant transporters from thosemea-
sured in vitro and assuming the same net transporter uptake scalar
(RAF) values as determined for metformin, it was possible to capture
the change in metformin kinetics when co-administered with cimeti-
dine. In contrast, using the conventional model, a 500-fold decrease in
the in vitro OCT1 and OCT2 Ki estimates was required to simulate the
metformin — cimetidine interaction.
An 8 to 18-fold decrease in transporter Ki values is consistent with
other attempts to recover transporter-mediated DDIs for solute carriers
(Greupink et al., 2013; Hsu et al., 2014; Li et al., 2014; Varma et al.,
2012). This discrepancy may reﬂect inappropriate in vitromethodology
or data analysis in the determination of Ki, or an incorrect assumption of
competitive inhibition. The cimetidine Ki values used in the current
study were obtained from in vitro experiments in which both OCT or
MATE transporters were acting as uptake transporters (Ito et al.,
2012). This means that the assumed concentration for inhibition (that
applied to the incubation media) should be reasonably consistent with
that at the transporter binding site. However, the MATE transporters
could only be maintained in this orientation by applying a rich potassi-
um ion concentration in themedia, whichmay impact its function to an
extent that the Ki estimate is inconsistent with its intrinsic value as an
efﬂux transporter in vivo. Another factor to consider relates to the po-
tential for MATE1 mediated efﬂux of metformin into bile. Although
MATE1 is expressed on the canalicular membrane of human hepato-
cytes (Otsuka et al., 2005), the lack of detectable metformin in faeces
after an intravenous dose and lack of secondary peaks precludes a
clear role for this transporter in the liver, leading to its exclusion from
our model (Pentikainen et al., 1979; Tucker et al., 1981). However, if
MATE1 biliary efﬂux of metformin was found to be signiﬁcant, its inhi-
bition by cimetidine may contribute to the observed DDI. In light of
these observations it is recommended to investigate a range of inhibitor
Ki values (e.g. up to 20-fold lower than the in vitro value) when using
themetforminmodel in prospective simulationswith OCT/MATE trans-
porter inhibitors.
Cimetidine is a weak inhibitor of CYP2D6 and CYP3A4 with Ki esti-
mates of approximately 40 μM and 160 μM, respectively (Madeira
et al., 2004; Martinez et al., 1999). As the metformin model included a
minor metabolic clearance component, it is possible that inhibition of
this component could contribute to the DDI. However, for CYP3A4, the
enzyme which has shown evidence of metformin metabolism (Choi
et al., 2010), this Ki estimate is 15-fold higher than the simulated max-
imum unbound concentration of cimetidine in the liver after 400 mg
BID dosing. On this basis it is likely that any metabolic component to
the observed DDI would be very minor. Although the clinical signiﬁ-
cance of the DDI between metformin and cimetidine is likely to be lim-
ited, this is not true of all DDIs involving renal OCT2 and MATE
transport. The anticancer drug cisplatin is a substrate for OCT2, MATE1
and MATE2-K in the proximal tubule and its use is accompanied by a
high risk of nephrotoxicity, linked to signiﬁcant renal accumulation
(Sprowl and Sparreboom, 2014). It has been suggested that cimetidine
(Sprowl et al., 2013b) and erlotinib (Sprowl et al., 2013a) may protect
against cisplatin induced nephrotoxicity through inhibition of OCT2.
The current study highlights the potential impact of MATE1/2-K inhibi-
tion in this setting, and a role for PBPKmodelling in clarifying the under-
lying processes. The coadministration of the OCT1 inhibitor verapamil
has been associated with a decrease to the glucose lowering effect of
metformin in the absence of signiﬁcant changes in its plasma concentra-
tion or urinary excretion (Cho et al., 2014). This indicates the need forfurther elaboration of the PBPK model for metformin that accounts for
pharmacodynamics changes mediated through the modiﬁcation of
transport affecting access of the drug to sites of action in both liver
and gut (Gong et al., 2012; McCreight et al., 2016).
5. Conclusion
We believe that, while highlighting some signiﬁcant deﬁciencies in
currently available data, the PBPK model that we have developed for
metformin with electrochemical modulation of the rate of hepatic up-
take by OCT1 and renal uptake by OCT2 moves forward understanding
of the use of this compound as a model substrate for predicting OCT
and MATE mediated DDIs.
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